美蓝和专利蓝在乳癌前哨淋巴结活检中作用的研究

Study of sentinel node biopsy with methylene blue and patent blue violet injection in patients with breast cancer

目的 探讨美蓝及专利蓝两种蓝染剂鉴别前哨淋巴结 (SLN )的成功率及预测乳癌腋淋巴结转移的准确性。方法 从 1999年 10月～ 2 0 0 1年 4月我科收治的乳癌病例中选取94例实施了前哨淋巴结活检 (SNB) ,其中于术中在乳腺肿块周围腺体内注射 1%美蓝 32例(美蓝组 )、注射 1%专利蓝 6 2例 (专利蓝组 )、以鉴别定位SLN。全部病例都实施了腋淋巴结清扫术。结果 SLN鉴别的成功率美蓝组和专利蓝组分别为 6 5 .6 % (2 1/ 32 )和 88.7% (5 5 /6 2 ) (P <0 .0 1) ;预测腋淋巴结转移状态准确性分别为 90 .5 % (19/ 2 1)和 98.2 % (5 4/ 5 5 ) (P>0 .0 5 )。结论 与美蓝比 ,专利蓝是较理想的乳癌SNB的生物活性染料示踪剂。

Objective To study the identification rate of sentinel lymph node (SLN) in patients with breast cancer (BC) and the accuracy in predicting axillary lymph node(ALN) metastasis using methylene blue (MB) and patent blue violet (PBV) injection. Methods From October, 1999 to April, 2001, 94 patients with BC were selected for this study. Of them, 32 patients were injected with 1% MB and 62 patients with 1% PBV to identify SLN. All 94 patients underwent the axillary lymph node dissection. Results In MB group and PBV group , the SLN identification rate were 65.6% (21/32), 88.7% (55/62); the accuracy rate to predict axillary lymph node status were 90.5% (19/21), 98.2% (54/55) respectively. Conclusion Compared with MB ,PVB is the more ideal vital blue dye in identification of SNB.